Surendra Purohit, MD
Surgery · Covington, LANPI 1265506703
Payments from drug & device makers
Across 146 payments — averaging $20.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$532
- Intuitive Surgical$446
- Bayer$380
- Urogen Pharma, Inc.$259
- Antares Pharma, Inc.$168
- Coloplast$124
- plus $1K from 35 others
What the payments were for
- Travel & lodging$1655%
- Food & beverage$2,89495%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 33 | $532 |
| Intuitive Surgical | 4 | $446 |
| Bayer | 24 | $380 |
| Urogen Pharma, Inc. | 8 | $259 |
| Antares Pharma, Inc. | 8 | $168 |
| Coloplast | 5 | $124 |
| Novo Nordisk | 8 | $116 |
| Davol Inc. | 1 | $81 |
| Clarus Therapeutics Inc. | 5 | $75 |
| Boston Scientific | 4 | $73 |
| Pfizer | 4 | $73 |
| Blue Earth Diagnostics | 3 | $55 |
| Axonics, Inc. | 3 | $48 |
| Laborie Medical Technologies Corp. | 2 | $46 |
| Tolmar, Inc. | 2 | $44 |
| Johnson & Johnson(2 entities) | 2 | $42 |
| C. R. Bard, Inc. & Subsidiaries | 2 | $41 |
| 180 Medical, Inc. | 2 | $40 |
| GSK | 2 | $39 |
| Civco Medical Instruments | 2 | $38 |
| Myriad Genetic Laboratories, Inc. | 2 | $35 |
| Endogastric Solutions, Inc | 1 | $28 |
| Tolmar Pharmaceuticals, Inc. | 1 | $21 |
| Pacira Pharmaceuticals Incorporated | 1 | $20 |
| Olympus America Inc. | 1 | $19 |
| TELA Bio, Inc. | 1 | $19 |
| Esperion Therapeutics, Inc. | 1 | $18 |
| BD | 1 | $17 |
| Medtronic | 1 | $15 |
| Mission Pharmacal Company | 1 | $15 |
| Amgen | 1 | $15 |
| Baudax Bio Inc. | 1 | $14 |
| Acerus Pharmaceuticals Corporation | 1 | $14 |
| Photocure Inc | 1 | $14 |
| Merck | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
| AstraZeneca | 1 | $11 |
| Teleflex LLC | 1 | $11 |
| Melinta Therapeutics, LLC | 1 | $11 |
| Sumitomo Pharma America, Inc. | 1 | $8 |
| Phathom Pharmaceuticals, Inc. | 1 | $5 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,059 in reported general payments places this provider in the 60th percentile of 381 surgery providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 141 | $117,655 |
| JanuviaSitagliptin Phosphate | 81 | $80,142 |
| JardianceEmpagliflozin | 47 | $53,973 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 47 | $48,160 |
| OzempicSemaglutide | 39 | $48,092 |
| JanumetSitagliptin Phos/Metformin Hcl | 56 | $42,952 |
| FarxigaDapagliflozin Propanediol | 40 | $33,534 |
| MyrbetriqMirabegron | 34 | $26,455 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 22 | $25,185 |
| GemtesaVibegron | 23 | $14,740 |
| RybelsusSemaglutide | 11 | $14,040 |
| LinzessLinaclotide | 13 | $11,929 |
| Breo ElliptaFluticasone/Vilanterol | 21 | $11,406 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 13 | $8,827 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 47 | $8,326 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| MerckJanuvia, Janumet, Janumet Xr | $14 | $148,278159 claims |
| PfizerEliquis, Premarin | $73 | $122,024159 claims |
| Novo NordiskOzempic, Rybelsus | $116 | $62,13350 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $39 | $59,56568 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Bevespi Aerosphere | $11 | $47,75666 claims |
| Astellas Pharma US IncMyrbetriq | $532 | $26,45534 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $8 | $14,74023 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 381 surgery providers in Louisiana.
Other surgery in Covington
- James RedmannCovington$42K
- Ralph CorsettiCovington$29K
- Thomas LavinCovington$19K
- Jacob DaigleCovington$14K
- Matthew FrenchCovington$12K
- John TaborBaton Rouge$567K
- Ari CohenNew Orleans$406K
- Carlos GalvaniNew Orleans$352K
- Karl LeblancBaton Rouge$341K
- Douglas SlakeyNew Orleans$318K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.